Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
6506-37-2
Molecular formula
C9H14N4O3
Molecular weight
226.23 g/mol
Drug class
5-nitroimidazolehypoxic-cell radiosensitiser and antiprotozoal agent
Mechanism of action
Under low-oxygen conditions, nitroimidazole reduction produces reactive intermediates that mimic oxygen fixation of radiation-induced DNA damage, increasing radiosensitivity of hypoxic tumour cells. It also produces DNA damage in susceptible protozoa and anaerobic organisms.
Indications / reported uses
Used as a radiosensitiser with radiotherapy for selected head-and-neck squamous-cell carcinomas in countries where authorised
Antiprotozoal and anaerobic antibacterial uses are country- and product-specific and should not be inferred from the radiosensitiser indication
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Nimorazole Environmental Risk Assessment (ERA) (the Nimorazole ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.